Treatment of Hypertension: A Review
- PMID: 36346411
- DOI: 10.1001/jama.2022.19590
Treatment of Hypertension: A Review
Abstract
Importance: Hypertension, defined as persistent systolic blood pressure (SBP) at least 130 mm Hg or diastolic BP (DBP) at least 80 mm Hg, affects approximately 116 million adults in the US and more than 1 billion adults worldwide. Hypertension is associated with increased risk of cardiovascular disease (CVD) events (coronary heart disease, heart failure, and stroke) and death.
Observations: First-line therapy for hypertension is lifestyle modification, including weight loss, healthy dietary pattern that includes low sodium and high potassium intake, physical activity, and moderation or elimination of alcohol consumption. The BP-lowering effects of individual lifestyle components are partially additive and enhance the efficacy of pharmacologic therapy. The decision to initiate antihypertensive medication should be based on the level of BP and the presence of high atherosclerotic CVD risk. First-line drug therapy for hypertension consists of a thiazide or thiazidelike diuretic such as hydrochlorothiazide or chlorthalidone, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker such as enalapril or candesartan, and a calcium channel blocker such as amlodipine and should be titrated according to office and home SBP/DBP levels to achieve in most people an SBP/DBP target (<130/80 mm Hg for adults <65 years and SBP <130 mm Hg in adults ≥65 years). Randomized clinical trials have established the efficacy of BP lowering to reduce the risk of CVD morbidity and mortality. An SBP reduction of 10 mm Hg decreases risk of CVD events by approximately 20% to 30%. Despite the benefits of BP control, only 44% of US adults with hypertension have their SBP/DBP controlled to less than 140/90 mm Hg.
Conclusions and relevance: Hypertension affects approximately 116 million adults in the US and more than 1 billion adults worldwide and is a leading cause of CVD morbidity and mortality. First-line therapy for hypertension is lifestyle modification, consisting of weight loss, dietary sodium reduction and potassium supplementation, healthy dietary pattern, physical activity, and limited alcohol consumption. When drug therapy is required, first-line therapies are thiazide or thiazidelike diuretics, angiotensin-converting enzyme inhibitor or angiotensin receptor blockers, and calcium channel blockers.
Similar articles
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981. JAMA. 2002. PMID: 12479763 Clinical Trial.
-
Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.J Hypertens. 2015 Feb;33(2):195-211. doi: 10.1097/HJH.0000000000000447. J Hypertens. 2015. PMID: 25485720 Review.
-
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008. Clin Ther. 2008. PMID: 18840367 Clinical Trial.
-
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.JAMA. 2005 Apr 6;293(13):1595-608. doi: 10.1001/jama.293.13.1595. JAMA. 2005. PMID: 15811979
-
Moderately Elevated Blood Pressure: A Systematic Review [Internet].Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Sep. SBU Yellow Report No. 170/1U. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Sep. SBU Yellow Report No. 170/1U. PMID: 28876740 Free Books & Documents. Review.
Cited by
-
implementation of healthy heart ambassador to improve blood pressure control at community health centers in Texas.BMC Health Serv Res. 2024 Sep 20;24(1):1105. doi: 10.1186/s12913-024-11485-z. BMC Health Serv Res. 2024. PMID: 39304836 Free PMC article.
-
An Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) Method for Qualifying DAPB in Rat Plasma and Application to Pharmacokinetic Studies.Molecules. 2024 Jan 22;29(2):541. doi: 10.3390/molecules29020541. Molecules. 2024. PMID: 38276619 Free PMC article.
-
Emergence of the brain-border immune niches and their contribution to the development of neurodegenerative diseases.Front Immunol. 2024 May 28;15:1380063. doi: 10.3389/fimmu.2024.1380063. eCollection 2024. Front Immunol. 2024. PMID: 38863704 Free PMC article. Review.
-
Traditional Chinese medicine for cardiovascular disease: efficacy and safety.Front Cardiovasc Med. 2024 Dec 3;11:1419169. doi: 10.3389/fcvm.2024.1419169. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39691499 Free PMC article. Review.
-
The neutrophil-to-lymphocyte ratio is associated with all-cause and cardiovascular mortality among individuals with hypertension.Cardiovasc Diabetol. 2024 Apr 2;23(1):117. doi: 10.1186/s12933-024-02191-5. Cardiovasc Diabetol. 2024. PMID: 38566082 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical